

**INTRODUCTION**

Malaria is a life threatening protozoal disease, transmitted by the infected Anopheline mosquitoes, caused by parasites known as Plasmodium (*P. falciparum*, *P. vivax*, *P. malariae* and *P. ovale*). The fifth species of plasmodium detected infecting humans in South-Eastern Asian countries since 2004 is *P. knowlesi*, commonly known as “monkey malaria parasite”.<sup>1</sup>

**GLOBAL SCENARIO**

It is a major public health problem responsible for substantial morbidity, mortality and economic loss. Its transmission is ongoing in 108 countries containing 3 billion people, out of which 1.2 billion are high risk cases and causing 1 million deaths each year.<sup>2</sup> In 2015 WHO documented 214 million symptomatic cases and 438,000 deaths from malaria.<sup>2</sup> *P. falciparum* malaria is the predominant infectious disease in tropical and sub-tropical countries with an estimated global incidence of 207 million cases and 627,000 deaths reported in 2012. (WHO)<sup>3</sup>

**INDIAN SCENARIO**

At present official figures for malaria in India, available at National Vector Borne Disease Control Programme

(NVBDCP) indicate 0.7-1.6 million confirmed cases and 400-1000 deaths annually.

According to World Malarial Report 2014, 22% (275.5m) of India’s population, live in high transmission (>1 per 1000 population) areas, 67% (858.9m) live in low transmission (0-1 cases per 1000 population) areas and 11% (137.7m) live in malaria free (0 cases) areas<sup>4</sup> (Figure 1).

With a population of 36.7 million (3.5%) the state of Odisha contributes about 25% of the total annual malaria cases, more than 40% of *P. falciparum* malaria cases and nearly 20-30% of deaths caused by malaria in India, followed by Meghalaya, Mizoram, Maharashtra, Rajasthan, Gujarat, Karnataka, Goa, Southern Madhya Pradesh, Chattisgarh and Jharkhand that also report significant number of malaria cases and deaths.<sup>4</sup>

**DIAGNOSIS OF MALARIA**


Malaria cases are diagnosed clinically and supported by laboratory investigations.

**Clinical Diagnosis**

The earliest symptoms of malaria are very non-specific and variable that includes fever with chill and rigor, headache, dizziness, anorexia, nausea, vomiting, loose motion etc. and very often they are received in secondary and tertiary care centres with complications like cerebral malaria, renal failure, hypoglycaemia, anaemia, respiratory distress or septicaemia. Clinical diagnosis of malaria is challenging in most tropical countries as it needs high degree of suspicion in both endemic and non-endemic areas, because malaria alone and with complications can mimic many other diseases like dengue fever, leptospirosis, influenza, hepatitis, enteric fever, scrub typhus, all types of viral encephalitis and gastroenteritis. It must be considered in the differential diagnosis of sepsis in pregnant woman arising in the uterus or urinary tract. The non-specific nature of clinical signs and symptoms of malaria may promote indiscriminate use of antimalarials due to over-treatment or non-treatment of other diseases in malaria endemic areas.

**Laboratory Diagnosis**

Rapid and effective malaria diagnosis decreases both patient’s suffering and community transmission. In the laboratory, malaria is diagnosed using different techniques e.g. conventional microscopic diagnosis by staining thin and thick peripheral blood smears, quantitative buffy coat (QBC) method, and rapid diagnostic tests (RDT) and



**Fig. 1: Malaria endemic areas in India**

**Table 1: Comparison of Rapid Diagnostic Tests for Malaria Antigens**

	<b>PfHRP2 tests</b>	<b>PfHRP2 and PMA test</b>	<b>pLDH test</b>
<b>Target antigen</b>	Histidine rich protein 2 of <i>P. falciparum</i> , water soluble protein expressed on RBC membrane	Pan-specific <i>Plasmodium</i> aldolase. Parasite glycolytic enzyme produced by all species and PfHRP2	Parasite lactate dehydrogenase. Parasite glycolytic enzyme produced by all species
<b>General test format</b>	2 lines	3 lines	3 lines
<b>Capability</b>	Detects <i>P. falciparum</i> only	Can detect all 4 species	Can detect all 4 species
<b>Non-falciparum species</b>	Not detected	Detected; differentiation between the 3 not possible	Detected; differentiation between the 3 not possible
<b>Mixed infections of <i>P. falciparum</i> with non-falciparum species</b>	Appear as <i>P. falciparum</i> ; differentiation not possible	Appear as <i>P. falciparum</i> ; differentiation not possible	Appear as <i>P. falciparum</i> ; differentiation not possible
<b>Detection limit</b>	>40-100 parasites/ $\mu$ L	Higher for <i>P. vivax</i> and other non-falciparum species	> 100-200 parasites/ $\mu$ L for <i>P. falciparum</i> and <i>P. vivax</i> ; may be higher for <i>P. malariae</i> and <i>P. ovale</i>
<b>Post-treatment persistence of antigens</b>	Reported up to 31 days	Reported; longer for pan specific antigenemia than for PfHRP2	Reported up to 1-3 weeks
<b>Cross-reactivity between malarial species</b>	Reported	Reported	Reported
<b>Cross-reactivity with auto antibodies</b>	Reported, high (up to 83% with rheumatoid factor)	Not known	Reported. low (3.3% with rheumatoid factor)
<b>Indication of viability of parasites</b>	No	No	Positive test indicates presence of viable parasitemia

molecular diagnostic methods such as polymerase chain reaction (PCR) amplification of parasitic nucleic acid.

### Peripheral Blood Smear Examinations

Accurate and timely diagnosis of malaria infections in febrile patients is a critical part of case management. Microscopic examination of stained blood smear remains the gold standard practice for malaria till date. Though considered as advantageous for accurate identification, species detection, parasite density estimation, low cost test, its parasite detection limitation is estimated to be 4-20 parasites/ $\mu$ l blood but under field conditions a threshold of about 50-100 parasites/ $\mu$ l is more justified.<sup>5</sup> More over its accuracy depends upon quality of microscope experience and training of microscopists and staining procedure and time consuming observations, added to that PHC's clinic examine blood smears from a large no. of clinically suspected patients with the help of one or two trained microscopists resulting in misleading interpretation and under estimation of malaria parasite.<sup>6</sup>

At any parasitaemia, more is the no. of mature stage parasites poorer is the prognosis. In general if more than 50% of peripheral blood parasites are at the tiny ring stage (i.e diameter of nucleus is less than 50% of the diameter of cytoplasm rim), the prognosis is relatively good. If more than 20% of parasites contain visible pigment (i.e. mature trophozoites or schizonts), the prognosis is relatively bad.

The presence of malaria pigment on polymorphonuclear leucocytes (PMN) (neutrophils) is a useful indication of the diagnosis of malaria, especially in anaemic children and in patients of severe malaria with absent or low parasitaemia.<sup>1</sup> If more than 5% PMN's contains malaria pigment then prognosis worsens.

### QBC Test

These technique uses epi-fluorescent microscope that detects malaria parasite DNA when stained with fluorescent dyes e.g. acridine-orange. It is a simple, rapid and sensitive test for diagnosing malaria but it requires specialised instrumentations which is more costly than conventional light microscopy and is poor at determining species and numbers of parasites.

### Rapid Diagnostic Test (RDT)

Over past two decades RDTs for malaria case identification has been developed and tested as an alternative to microscopy. This is based on the principles of detection of antigen released from parasitized RBCs. The result is a coloured test line obtained in 5-20 minutes. RDTs incorporate antibodies against Histidine rich protein 2 (HRP2) specific for *P. falciparum*, Plasmodium specific LDH (pLDH) for all malaria species and also Plasmodium aldolase.

Several studies compared RDTs based on these antigens, with different results in terms of sensitivity, specificity,

**Table 2: Comparison of Peripheral Blood Smear Examination and RDTs for Malaria**

	Peripheral Smear	Rapid Diagnostic Tests
<b>Format</b>	Slides with blood smear	Test strip
<b>Equipment</b>	Microscope	Kit only
<b>Training</b>	Trained microscopist	'Anyone with a little training'
<b>Test duration</b>	20-60 minutes or more	5-30 minutes
<b>Test result</b>	Direct visualization of the parasites	Color changes on antibody coated lines
<b>Capability</b>	Detects and differentiates all plasmodia at different stages	Detects malaria antigens (PfHRP2/PMA/pLDH) from asexual and/or sexual forms of the parasite
<b>Detection threshold</b>	5-10 parasites/ $\mu$ L of blood	1 00-500/ $\mu$ L for <i>P. falciparum</i> , higher for non-falciparum
<b>Species differentiation</b>	Possible	Cannot differentiate among non-falciparum species; mixed infections of <i>P. falciparum</i> and non-falciparum appear as <i>P. falciparum</i>
<b>Quantification</b>	Possible	Not possible
<b>Differentiation between sexual and asexual stages</b>	Possible	Not possible
<b>Disadvantages</b>	Availability of equipment and skilled microscopists, particularly at remote areas and odd hours	Unpredictable efficiency at low and very high parasitemia; cross reactions among plasmodial species and with auto-antibodies; persistence of antigens
<b>Status</b>	Gold standard	Not yet approved by the FDA
<b>Cost per test</b>	US\$ 0.12-0.40	US\$ 1 .20-13.50

positive and negative predictive values. Since 2010, WHO has recommended either RDT or microscopy for confirmation of suspected malaria cases before treatment.<sup>7</sup> The RDT consumption has increased in developing countries for the past few years. The WHO has recommended a minimum standard of 95% sensitivity at parasite densities of 100/ $\mu$ L. Most RDTs today have achieved >95% sensitivity goal for *P. falciparum* but not for non *P. falciparum*<sup>5</sup> (Table 1). RDTs, in field conditions require to be stable under extremes of temperature and humidity during use and storage.

In 2010, *P. falciparum* lacking *pfhrp2* and/or *pfhrp3* genes were first isolated from infected human subjects in the Amazon region of Peru. Other endemic regions also reported false negative results using RDTs based on *pfhrp2* due to gene deletions.<sup>7</sup>

A lot of RDT negative cases often responding to anti-malaria questions not only to establish the genetic make-up of Indian population but also to the humidity, temperature resistant RDT Kit's standardisation.

Both microscopy and RDT cannot detect parasite densities of less than 100 parasites per ml particularly in field conditions where a symptomatic carriers have a much lower parasite density<sup>8</sup> (Table 2).

### Polymerised Chain Reaction (PCR)

During the past decade highly sensitive and specific

nucleic acid amplification techniques have been developed to detect malaria parasite those are PCR, quantitative PCR (qPCR), Reverse transcriptase PCR (RT-PCR).

But PCR & Loop mediated isothermal amplification (LAMP) are the techniques used for detecting parasite DNA. These are highly sensitive and vary useful for detecting mixed infections in particular at low parasitaemia where conventional microscopy or RDT will be of no help.

PCR detects < 10 parasite/ $\mu$ L, LAMP detects 5-10 parasite/ $\mu$ L and NASBA's (Nucleic Acid Sequence Based Amplification) selection limit is < 1 parasite/ $\mu$ L. For field based epidemiological study PCR based methods are most useful to quantify, detect and diagnose low density parasitaemia whether asexual or gametocyte forms. In developing countries these tests are performed in reference centres as it is impractical to use for diagnosis of malaria in standard clinical settings. At present according to WHO, molecular diagnostic tools based on nucleic acid amplification techniques don't have a role in the clinical management of malaria.<sup>2</sup>

### CONCLUSION

The foremost point in the malaria case management is prompt and accurate diagnosis that can be obtained by proper travel history, clinical diagnosis, confirmation by specific diagnostic procedures having high accuracy. The diagnostic challenges in India can be alleviated

if a suitable, simple, sensitive and low cost diagnostic procedure with high specificity would be available.

## REFERENCES

1. Nicholas J. White, Joel G. Breman: Malaria; Dennis L Kasper, Stephen L Hauser, J Larry Jameson, Anthony S. Fauci, Dan L Longo, Joseph Loscalzo: Harrison's principles of Internal Medicine, 19<sup>th</sup> edition, McGraw Hill Education, USA, 2015, 1368-1386.
2. [www.who.int/malaria/media/world-malaria-report-2015/en/](http://www.who.int/malaria/media/world-malaria-report-2015/en/) .
3. Praveen K Sahu, Sanghamitra Satpathi, Prativa K Behera, Saroj K Mishra, Sanjib Mohanty and Samuel Crocodile Wassmer: Pathogenesis of cerebral malaria: new diagnostic tools, biomarkers and therapeutic approaches: *Frontiers in Cellular and Infection Microbiology*, 2015, vol 5, article 75
4. <http://www.malariasite.com/malaria-india/> .
5. Chansuda Wongsrichanalai, Mazie J. Barcus, Sinuon Muth, Awalludin Sutamihardja, Walter H. Wernsdorfer: A Review of Malaria Diagnostic Tools: Microscopy and Rapid Diagnostic Test (RDT). *Am J Trop Med Hyg* 2007; 77 (suppl6), 119-127.
6. Praveen K Bharti, Nipun Silawat, Puspendra P Singh, Mrigendra P Singh, Manmohan Shukla, Gyan Chand, Aditya P. Dash et al: *Malaria Journal* 2008; 7:126.
7. Tamaki Kobayashi, Dionicia Gamboa, Daouda Ndiaye, Liwang Cui: Malaria Diagnosis across the International centres of Excellence for Malaria Research: Platforms, Performance and Standardisation. *Am J Trop Med Hyg* 2015; 93 (suppl 3),99-109.
8. Eniyou C. Oriero, Jan Jacobs, Jean-Pierre Van Greetryden, Davis Nwakanma, Umberto D'Alessandro: Molecular-based isothermal tests for field diagnosis of malaria and their potential contribution to malaria elimination. *J Antimicrob Chemother* 2015; 70:2-13.